<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667585</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00105899</org_study_id>
    <nct_id>NCT04667585</nct_id>
  </id_info>
  <brief_title>Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx</brief_title>
  <official_title>Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx Using Metabolic Signature From Interim 18FDG-PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use intra-treatment 18FDG-PET/CT during definitive radiation&#xD;
      therapy for human papillomavirus (HPV)-related oropharyngeal cancer (OPC) as an imaging&#xD;
      biomarker to identify and select patients with a favorable response for chemoradiation dose&#xD;
      de-escalation. This study will prospectively evaluate the clinical outcomes for patients&#xD;
      undergoing dose de-escalation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">April 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants undergo either reduced radiation dose or standard radiation dose based on the metabolic signature from an Interim 18FDG-PET/CT</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>from initiation of radiation therapy through study completion, an average of 2 years</time_frame>
    <description>defined as the time between initiation of radiation treatment and the first documented recurrence of disease or death due to any cause as measured by medical record abstraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>locoregional progression-free survival</measure>
    <time_frame>from initiation of radiation therapy through study completion, an average of 2 years</time_frame>
    <description>as measured by abstraction from the medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant disease-free survival</measure>
    <time_frame>from initiation of radiation therapy through study completion, an average of 2 years</time_frame>
    <description>as measured by abstraction from the medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>from initiation of radiation therapy through study completion, an average of 2 years</time_frame>
    <description>as measured by abstraction from the medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival correlation in PET/CT responders versus PET/CT non-responders</measure>
    <time_frame>2 years</time_frame>
    <description>as measured by the difference in median Kaplan-Meyer values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute adverse events</measure>
    <time_frame>7 weeks</time_frame>
    <description>as measured by the number of participants who experience dermatitis, mucositis, xerostomia, dysphagia, dysgeusia, neutropenia, thrombocytopenia, nausea, vomiting, renal toxicity, and hearing loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>as measured by the number of participants who experience xerostomia, dysphagia, dysgeusia, trismus, lymphedema, superficial soft tissue fibrosis, hypothyroidism and periodontal disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Oropharynx Cancer</condition>
  <arm_group>
    <arm_group_label>Interim PET-CT with dose de-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an interim PET-CT approximately 2 weeks into radiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interim PET-CT with standard radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>De-escalated radiation dose</intervention_name>
    <description>Reduced dose of radiation applied to remaining radiation therapy when favorable interim PET-CT signature is produced</description>
    <arm_group_label>Interim PET-CT with dose de-escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard radiation dose</intervention_name>
    <description>Standard dose of radiation applied to remaining radiation therapy when favorable PET-CT signature is not produced</description>
    <arm_group_label>Interim PET-CT with standard radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)</intervention_name>
    <description>The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.</description>
    <arm_group_label>Interim PET-CT with dose de-escalation</arm_group_label>
    <arm_group_label>Interim PET-CT with standard radiation</arm_group_label>
    <other_name>18 FDG-PET/CT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic documentation of squamous cell carcinoma of the oropharynx with&#xD;
             p16-positive immunohistochemical staining and/or positive HPV in situ hybridization&#xD;
             (ISH) and/or positive HPV PCR&#xD;
&#xD;
          -  Stage I-III (AJCC 8th edition) with plan for concurrent chemotherapy per standard of&#xD;
             care treatment&#xD;
&#xD;
          -  Zubrod/ECOG score of 0-1&#xD;
&#xD;
          -  Weight loss &lt;10% in the 3 months prior to diagnosis&#xD;
&#xD;
          -  â‰¥ 18 years of age&#xD;
&#xD;
          -  No prior chemotherapy for their current cancer diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiotherapy to the head and neck&#xD;
&#xD;
          -  Medical contraindications to radiation therapy&#xD;
&#xD;
          -  Absence of gross disease on imaging prior to beginning radiation therapy&#xD;
&#xD;
          -  Distant metastatic disease&#xD;
&#xD;
          -  Medical contraindication to PET/CT&#xD;
&#xD;
          -  History of active cancer other than non-melanoma skin cancer within the last 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Brizel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DUHS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvonne Mowery, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DUHS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Franklin, BSN, RN, OCN</last_name>
    <phone>(919) 668-3726</phone>
    <email>heather.mccullough@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Franklin, RN BSN OCN</last_name>
      <phone>919-668-3726</phone>
      <email>heather.mccullough@duke.edu</email>
    </contact>
    <investigator>
      <last_name>David Brizel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Mowery, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Raleigh Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Franklin, BSN RN OCN</last_name>
      <phone>919-668-3726</phone>
      <email>heather.mccullough@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET-CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

